| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | PD6050B | |||
| Carrier Free | D6050B | |||
| Carrier Free | S6050B | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | 7270-IL-025/CF | |||
| Carrier Free | 7270-IL-010/CF | |||
| Carrier Free | 7270-IL-100/CF | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | 206-IL-025/CF | |||
| Carrier Free | 206-IL-001MG/CF | |||
| Carrier Free | 206-IL-050/CF | |||
| Carrier Free | 206-IL-200/CF | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | 406-ML-005/CF | |||
| Carrier Free | 406-ML-025/CF | |||
| Carrier Free | 406-ML-200/CF | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | MAB206-SP | |||
| Carrier Free | MAB206-500 | |||
| Conjugate | Catalog # | Availability | Size | Price |
|---|---|---|---|---|
| Biotin | NBP1-42761 | |||
| HRP | NBP1-42762 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | AF-206-SP | |||
![N/A IL-6 [HRP]](http://images.novusbio.com/fullsize2/IL6_D6050_ELISA_2663.jpg "N/A IL-6 [HRP]")
![N/A IL-6 [HRP]](http://images.novusbio.com/fullsize2/IL6_D6050_ELISA_2664.jpg)
![N/A IL-6 [HRP]](http://images.novusbio.com/fullsize2/IL6_D6050_ELISA_2665.jpg)
![N/A IL-6 [HRP]](http://images.novusbio.com/fullsize2/IL6_D6050_ELISA_555.jpg)
![N/A IL-6 [HRP]](http://images.novusbio.com/fullsize2/IL6_D6050_ELISA_556.jpg)
![N/A IL-6 [HRP]](http://images.novusbio.com/fullsize2/IL6_D6050_ELISA_20.jpg)
![Toll-like receptor 4 (TLR4) silencing decreases endogenous levels of pro-inflammatory cytokines. a Effect of TLR2/4 silencing in breast cancer cells transfected with negative control (nc) siRNA, or siRNA directed against TLR2 mRNA (si#1 and si#2) or TLR4 mRNA (si#1 and si#2) was analyzed using quantitative real-time PCR; ***P <0.001 (analysis of variance (ANOVA)). b IL-6 (left) and IL-8 (right) ELISA on supernatants from MDA-MB-231 breast cancer cells transfected with nc siRNA, or siRNA directed against TLR2 mRNA (si#1 and si#2) or TLR4 mRNA (si#1 and si#2); n = 4. Error bars standard error of the mean (SEM); *P <0.05, **P <0.01, ***P <0.001 (ANOVA). c Boyden chamber migration assays. Migration of primary human myeloid cells towards supernatants from different cell lines indicated. Human primary peripheral blood mononuclear cells were isolated as previously described [48] and allowed to migrate through a Costar Transwell® Permeable Support 8.0-μm 24-well plate (Corning) to the supernatants of breast cancer supernatants cultured under serum-free conditions. Percentage of migrated CD11b+ cells was analyzed using a flow cytometer and CD11b-APC antibodies (BD Sciences); n = 4. Error bars SEM; *P <0.05, **P <0.01, ***P <0.001 (ANOVA). d Matrigel invasion assays. Invasion of lipopolysaccharide (LPS)-stimulated/un-stimulated MDA-MB-231 cells into matrigel invasion chambers (BD Sciences) as indicated: 25 × 103 MDA-MB-231 cells were stimulated or not with LPS and allowed to invade from 72 h. Amount of invaded cells was analyzed using crystal violet staining and manual counting in four separate experiments; n = 4. Error bars SEM; *P <0.05, **P <0.01, ***P <0.001 (Student’s t test) Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/26392082), licensed under a CC-BY license. Not internally tested by R&D Systems.](http://images.novusbio.com/fullsize/d6050_human-il-6-quantikine-elisa-kit-22820241721198.jpg)
![N/A IL-6 [HRP]](http://images.novusbio.com/fullsize2/DATA_IL6_M6000_ELISA_936.jpg "N/A IL-6 [HRP]")
![N/A IL-6 [HRP]](http://images.novusbio.com/fullsize2/IL-6_M6000_ELISA_415.jpg)
![N/A IL-6 [Biotin]](http://images.novusbio.com/fullsize2/DATA_IL6_DY406_ELISA_2322.jpg "N/A IL-6 [Biotin]")
![N/A IL-6 [Biotin]](http://images.novusbio.com/fullsize2/DATA_IL6_DY206_ELISA_1760.jpg "N/A IL-6 [Biotin]")
![N/A IL-6 [HRP]](http://images.novusbio.com/fullsize2/DATA_IL6_R6000_ELISA_1084.jpg "N/A IL-6 [HRP]")
![N/A IL-6 [HRP]](http://images.novusbio.com/fullsize2/IL-6_PR6000_ELISA_434.jpg)
![N/A IL-6 [Biotin]](http://images.novusbio.com/fullsize2/DATA_IL6_DY506_ELISA_2076.jpg "N/A IL-6 [Biotin]")
![Western Blot: IL-6 Antibody [NB600-1131] - Western Blot: IL-6 Antibody [HRP] [NBP1-42762] - Lane 1: Human IL-6. Lane 2: none. Load: 50 ng per lane. Primary antibody: none. Secondary antibody: Peroxidase Human IL-6 secondary antibody at 1:1,000 for 60 min at RT. Block: incubated with blocking buffer for 30 min at RT. Predicted/Observed size: 20 kDa for Human IL-6. Other band(s): none. Image using the HRP form of this antibody.](http://images.novusbio.com/fullsize/IL-6-Antibody-Western-Blot-NB600-1131-img0014.jpg "Western Blot: IL-6 Antibody [NB600-1131] - Western Blot: IL-6 Antibody [HRP] [NBP1-42762] - Lane 1: Human IL-6. Lane 2: none. Load: 50 ng per lane. Primary antibody: none. Secondary antibody: Peroxidase Human IL-6 secondary antibody at 1:1,000 for 60 min at RT. Block: incubated with blocking buffer for 30 min at RT. Predicted/Observed size: 20 kDa for Human IL-6. Other band(s): none. Image using the HRP form of this antibody.")
![Immunohistochemistry: IL-6 Antibody [NB600-1131] - GBM ECs express IL-6. Mouse GBM was induced by orthotopic injection of GL26 glioma cells into wild-type mouse. The brain sections that include normal brains and tumors were stained with anti-CD31, anti-IL-6, and anti-CSF-1 antibodies. Representative immunofluorescence images are shown. Right, enlarged area in normal and tumor tissues. Bar represents 50?um. Zoom-in factor: 4 Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/s41467-018-03050-0) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/IL-6-Antibody-Immunocytochemistry-Immunofluorescence-NB600-1131-img0015.jpg)
![Western Blot: IL-6 Antibody [NB600-1131] - Protein was resolved on a 4-20% Tris-Glycine gel by SDS-PAGE and transferred onto nitrocellulose. The blot shows detection of a band 21 kDa in size corresponding to anti-IL6 antibody. Molecular weight markers are also shown (MW). After transfer, the membrane was blocked for 30 minutes with 1% BSA-TBST. Detection occurred using peroxidase conjugated anti-Rabbit IgG secondary antibody diluted 1:40,000 in blocking buffer for 30 min at RT followed by reaction with FemtoMax chemiluminescent substrate.](http://images.novusbio.com/fullsize/IL-6-Antibody-Western-Blot-NB600-1131-img0013.jpg)
![Immunocytochemistry/ Immunofluorescence: IL-6 Antibody [NB600-1131] - GBM ECs express IL-6. a Human brain ECs were treated with glioma-CM for 24 h, & cell lysates were subjected to multiplex cytokine array analysis. Left, a representative blot. Right, quantified dot intensity of most significantly changed cytokines. b Human microvascular brain ECs were treated with glioma-CM that were harvested from different human glioma cells. Cell lysates were immunoblotted. c Human microvascular brain ECs & tumor-associated ECs isolated from different GBM patients were subjected to immunoblot analysis. d Mouse GBM was induced by orthotopic injection of GL26 glioma cells into wild-type mouse. The brain sections that include normal brains & tumors were stained with anti-CD31, anti-IL-6, & anti-CSF-1 antibodies. Representative immunofluorescence images are shown. Right, enlarged area in normal & tumor tissues. Bar represents 50 μm. Zoom-in factor: 4 Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29422647), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-1131_rabbit-polyclonal-il-6-antibody-310202416154648.jpg)
